White Paper
Navigating the Complex Realities of Biomarker Testing in Oncology
Oct 09, 2020
The focus of this white paper is to highlight the rapidly evolving biomarker landscape in oncology from clinical development to regulatory uncertainties to commercial implications. It will focus on the key challenges and success factors involved in launching targeted therapies with biomarkers and/or in vitro diagnostics, outline how to navigate the complex realities of biomarkers and how the industry needs to adapt for targeted therapies to ultimately reach patients without creating too much of a burden on the healthcare system.

Biomarker Testing In Oncology

Biomarkers are indicators of a patient’s likelihood to respond to certain treatments. By testing for predictive biomarkers, Oncologists can make more informed treatment decisions. Click on the link below to read the infographic.
Contact Us